SITC 2026: JNJ-87189401 (PSMAxCD28) Plus Pasritamig (KLK2xCD3): First-in-Human Phase 1 Results of Dual-Antigen T Cell Engager Therapy in Prostate Cancer

Johnson & Johnson reported Phase 1 results for its investigational combination of pasritamig and JNJ-9401 in advanced prostate cancer, showing 73% of patients achieved at least 50% PSA reduction. The combination targets KLK2 and PSMA proteins, with a favorable safety profile. The company is advancing to Phase 3 trials.

Johnson & Johnson reported phase 2 data on nipocalimab for Sjögren’s disease, to be presented at ACR Convergence 2026. Patients prioritized mouth dryness improvement; 33% of 15 mg/kg recipients saw ≥50% salivary flow increase vs. 16% on placebo. Study was unpeer-reviewed, with limitations noted.

In a Phase 3 trial, 58% of biologic-naive psoriatic arthritis patients treated with icotrokinra (ICOTYDE) achieved ACR20 response at Week 16, compared to 41% on placebo. The drug, approved for psoriasis, targets the IL-23 receptor, unlike other IL-23 pathway agents. Johnson & Johnson's ICONIC-PsA 2 trial will assess its efficacy in biologic-experienced patients.

Johnson & Johnson's JNJ-87189401 plus pasritamig showed promising results in mCRPC patients at the 2026 SITC Annual Meeting. The recommended dose had no severe adverse effects, with 73.3% achieving a PSA decline of at least 50%. The combination is being evaluated in a phase 3 trial.

Johnson & Johnson (JNJ) reported positive Phase 3 trial results for icotrokinra in psoriatic arthritis, meeting its primary endpoint. At week 16, 58% of patients on icotrokinra achieved ACR20 vs. 41% on placebo. JNJ shares closed at $276.22 on Nov. 6, before the announcement.

Johnson & Johnson (JNJ) reported that Icotyde, a therapy co-marketed with Protagonist Therapeutics (PTGX), showed success in a late-stage trial for psoriatic arthritis, according to the company. The drug is already FDA-approved for plaque psoriasis. Up to 30% of plaque psoriasis patients also develop psoriatic arthritis, per studies.